

Pro-Virus, Inc.

930 Clopper Road, Gaithersburg, MD 20878 (240) 631-2500 Fax: (240) 683-3794

FACSIMILE TRANSMITTAL**DATE:** APRIL 5, 2002**PLEASE DELIVER THE FOLLOWING PAGES TO:****NAME:** EXAMINER ZEMAN**GROUP ART UNIT:** 1645**COMPANY:** U.S. PATENT AND TRADEMARK OFFICE**FAX NO.** (703) 308-4242**THIS FACSIMILE IS BEING SENT BY:****NAME:** LEWIS KREISLER**Number of Pages (including this cover sheet):** 3If you do not receive all the pages please call Pro-Neuron at (240) 631-2500 x3277

Re: Inventor(s): Bell, et al.
Appl. No.: 09/664,444
Filed: September 18, 2000
For: ONCOLYTIC VIRUS
Atty. Ref. 18003

Transmitted herewith is/are the following document(s):

April 5, 2002 Communication in Response to Restriction Requirement, including certificate of facsimile transmission

Confidentiality Statement

This facsimile and the information it contains are intended to be a confidential communication only to the person to whom it is addressed. If you have received this facsimile in error, please notify us by telephone and return the original to this office by mail - thank you.

1645
RECEIVED
APR 26 2002
TECH CENTER 100/2800
FAX RECEIVED
APR 0 2002
GROUP 1600

OFFICIAL

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being facsimile transmitted (Fax No. (703) 308-4242) to the United States Patent and Trademark Office on the date shown below.

By: Lewis J. Kreisler
Lewis J. Kreisler
Reg. No. 38522

Date: 4/5/02

FAX RECEIVED

APR 05 2002

GROUP 1

OFFICE

RECEIVED
TECH CENTER 1600/2900

APR 26 2002

RECEIVED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Bell, et al.

Atty. Ref.: 18003

Appl. No.: 09/664,444

Art Unit: 1645

Conf. No.: 4773

Filed: September 18, 2000

Examiner: R. Zeman

For: ONCOLYTIC VIRUS

* * * * *

April 5, 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

COMMUNICATION IN RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the March 20, 2002 Office Action in connection with the above-identified application. A response to the Office Action is due April 20, 2002. Therefore this Communication is being timely filed.


The Office Action stated that restriction is required under 35 U.S.C. §121 to one of fourteen (14) groups as set forth in the Office Action. Applicants elect Group II (Claims 1, 5-13, 18-37, drawn to a method of reducing the viability of hematopoietic tumor cells by administering a virus, classified in class 424, subclass 93.1), with traverse.

Inventor(s): Bell, et al.
Application No.: 09/664,444
Page 2

Applicants respectfully request reconsideration and rejoinder of Groups I through VI. Groups I-VI are all in class 424, subclass 93.1. Accordingly, applicants submit that there would not be a serious burden on the Examiner to search these groups together.

It is believed that no fee is required in connection with the filing of this Communication. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,



Lewis J. Kreisler

Reg. No. 38522

Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794